Collaborative Innovation in Drug Discovery. Strategies for Public and Private Partnerships

Description

Can academia save the pharmaceutical industry?

The pharmaceutical industry is at a crossroads. The urgent need for novel therapies cannot stem the skyrocketing costs and plummeting productivity plaguing R&D, and many key products are facing patent expiration. Dr. Rathnam Chaguturu presents a case for collaboration between the pharmaceutical industry and academia that could reverse the industry's decline. Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships provides insight into the potential synergy of basing R&D in academia while leaving drug companies to turn hits into marketable products. As Executive Director of the High Throughput Screening Laboratories at the University of Kansas, one of the founding members of the Society for Biomolecular Sciences, and holder of eleven patents, Dr. Chaguturu has assembled a panel of experts from around the world to weigh in on issues that affect the two driving forces in medical advancement.

· Gain global perspectives on the benefits and potential issues surrounding collaborative innovation
· Discover how industries can come together to prevent another "Pharma Cliff"
· Learn how nonprofits are becoming the driving force behind innovation
· Read case studies of specific academia-pharma partnerships for real-life examples of successful collaboration
· Explore government initiatives that help foster cooperation between industry and academia

Dr. Chaguturu's 30 years of experience in new lead discovery and development and managing hit-to-lead projects lend him an informative perspective into the issues facing pharmaceutical progress. In Collaborative Innovation in Drug Discovery: Strategies for Public and Private Partnerships, he and his expert team provide insight into the various nuances of the debate.

Table of Contents

Dedication
Poem
Barry Bunin

Foreword
Ferid Murad

Preface
Rathnam Chaguturu

List of Contributors

Section 1: Perspectives on Collaborative Innovation
If I have seen further it is by standing on the shoulders of giants
—Isaac Newton

1. Productive Relationships in Research and Development between Government, Industry and Universities
Rory Hume

2. Divided We Fall
William Mattes

3. Innovation: Open Source and Nonprofit Models in Drug Discovery
James Shaeffer and Sarah MacDonald

4. The Changing Face of Innovation in Drug Discovery
Litao Zhang and Carl Decicco

5. Current Trends in Collaborative Drug Discovery and Strategies to De-risk Open Innovation-based Precompetitive Initiatives
Anuradha Roy and Rathnam Chaguturu

6. A Perspective on the Evolution of Collaborative Drug Discovery and Future Challenges
Chistopher Lipinski

Section 2: Governmental Initiatives Accelerate Pre-competitive Collaboration
Governments will always play a huge part in solving big problems.... They also fund basic research, which is a crucial component of the innovation that improves life for everyone
—Bill Gates

7. University-Industry Partnerships Matter
Anthony Boccanfuso

8. Trends in the Public Sector Adoption of Translational Research Approaches
Mark Scheideler

9. Partnerships for Drug Repositioning: Lessons from the CTSA Pharmaceutical Assets Portal
Kate Marusina, Dean Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron Cohen, Rafael Gacel-Sinclair, Pakou Vang, Peter Ruminski, Bruce Bloom, Pamela Nagasawa and Betty Guo

10. Drug Development Programs at the U.S. National Cancer Institute: Use of Public-Private Partnerships as a Catalyst to Advance Cancer Therapy
Jason Cristofaro

11. Non-Industrial Pharmaceutical Research in the BRIC Countries: Lessons for Drug Discovery Partnerships with Academic and Governmental Institutions
John Watson

12. Death of Drugs and Rebirth of Health Care: Indian Response to Discovery Impasse
Bhushan Patwardhan

Section 3: A Game Changer for Averting Future Pharma Cliff
Coming together is a beginning, staying together is progress, and working together is success
—Henry Ford

13. Accelerating Innovation in the Bioscience Revolution
Bernard Munos

14. Value-Driven Drug Development: Unlocking the Value of Your Pipeline
Valentina Sartori, Michael Steinmann, Petra Jantzer and Matthias Evers

15. Unlocking the Market Potential of Academic Research
Assem el Baghdady and Yasser el Baghdady

16. Collaborative Innovation in Pharmaceutical Industry: Approaches and Requirements
Monika Lessl and Asadullah Khusru

17. Close Contact: A Co-location Model for Academic-Industrial Partnerships in Drug Discovery
Peter Covitz and Terrence Ruddy

18. Success Factors and Obstacles in Academia-Industry Partnerships: A Case Study of a Graduate Program within the Bayer –University of Cologne "Privileged Partnership"
Stefan Herzig, Marion Rozowski and Ingo Flamme

19. Academic, Commercial, and Biodefense Case Studies for Collaborative Drug Discovery: Potential for Disrupting Drug Discovery
Barry Bunin and Sean Ekins

20. Access Platform: A Streamlined Integrative Partnering Process at SANOFI to Commercialize University-based Intellectual Property
Paul Eynott and Carole Fages

21. Entrepreneurship: Drug Discovery Innovation at Start-Up and Medium-Sized Biotechnology Companies
Allen Reitz and Kathleen Czupich

22. Chemical Consulting
Lester Mitscher

Section 4: Nonprofits Drive Bench to Bedside Innovation
Can't afford to innovate? Open up!
—Henry Chesbrough

23. Open Source Drug Discovery for Neglected Diseases
Tonny Johnson and Sanchayita Kar

24. The Myelin Repair Foundation Accelerated Research CollaborationTM Model: Innovative Disruption in Biomedical Research
Gali Hagel

25. Catalysis to Mass Action: The Evolution of CHDI Foundation, a Drug-Development Organization Devoted to Huntington's Disease
Allan Tobin

26. Lessons from the Past as a Means to the Future: Institut Pasteur as a Model Strategy
Spencer Shorte

27. Seeding Open Innovation Drug Discovery and Translational Collaborations to Leverage Government Funding: Case Study Involving Sanford-Burnham and Mayo Clinic
Thomas Chung, Sundeep Khosla, Andrew Badley and Michael Jackson

Section 5: Academic Screening Centers Come of Age
Open access high throughput drug discovery in the public domain is a Mount Everest in the making
—Rathnam Chaguturu

28. Finding the Middle Ground: Drug Discovery Technology in the Era of Academic Screening Centers
Nathan Blow

29. Open Innovation based Drug Discovery in Europe: Some Examples of National and Transnational European Initiatives Integrating Chemistry, Biology and Technology Platforms
Philip Gribbon

30. In Sickness and in Health - A Shotgun Marriage that's Flourishing
Horst Flotow and Alex Matter

31. A Flexible Model for Compound Management Facilities to Stimulate Collaborations in the Life Sciences
David Camp

Section 6: Intellectual Property and Technology Transfer
Everything that can be invented has ben invented
—Charles Duell

32. Successful Technology Transfer: Lessons from the Translational Medicine Research Collaboration
Assem el Baghdady

33. Challenges and Opportunities in Commercializing Academic Drug Discoveries
Christopher Paschall

34. The Pivotal Role of the Academic Entrepreneur and the Entrepreneurial University in Global Life Sciences
Donna Marie de Carolis

Section 7: Final Frontier
No one can whistle a symphony; it takes a whole orchestra to play it
—Halford E. Luccock

35. The Core Model: Drug Discovery and Development via Effective Translational Science and Public-Private Collaboration
Ibis Sanchez-Serrano

36. Using Market-Driven Collaboration to Accelerate Innovation in Biomedicine
Elizabeth Iorns

37. The Cost of Taking Eyes off the True End User-Focus on Patient Needs and Outcomes
Deborah Collyar

38. To Leash or Unleash the Power of Public-Private Collaboration: A Personal Perspective
Hakim Djaballah